Replies to post #117264 on Biotech Values

[jq1234]

They already have the ASPIRE trial running since last year, so I'm not sure that your point #2 is the most likely concern.

ASPIRE is carfilzomib in combination with Lenalidomide, and Dexamethasone in relapsed MM while FOCUS is the only randomized trial where carfilzomib as single agent in rrMM.

[genisi]

ONXX/carfilzomib European FOCUS Study

Previously, Estimated Study Completion Date was February 2012. Now, time to market in EU will probably be delayed. Although, the study design now incorporates planned interim analyses on the primary endpoint, so perhaps a chance for an earlier end of trial.